By Tony Fong

NEW YORK (GenomeWeb News) – As molecular diagnostics progresses toward becoming a routine part of healthcare, health plans are struggling with a host of issues from how to evaluate such tests to deciding which ones to cover.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.